Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Semi-Annual Changes to the NASDAQ Biotechnology Index

May 10th, 2008

Semi-Annual Changes to the NASDAQ Biotechnology Index

Abstract:
The NASDAQ OMX Group, Inc. ("NASDAQ") (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index(r) (Nasdaq:NBI), which will become effective with the market open on Monday, May 19, 2008.

The re-ranking will result in 5 securities being added to the Index. All securities are classified according to the Industry Classification Benchmark (ICB) as either biotechnology or pharmaceutical. The securities that meet the classification criteria then must meet other Index eligibility criteria including listing on the NASDAQ Global Market or the NASDAQ Global Select Market and meeting minimum requirements for market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.NASDAQ.com.

As a result of the re-ranking, AtheroGenics, Inc. (Nasdaq:AGIX), Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS), CuraGen Corp. (Nasdaq:CRGN), Labopharm, Inc. (Nasdaq:DDSS), NitroMed, Inc. (Nasdaq:NTMD), Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) and Verenium Corporation (Nasdaq:VRNM), will be removed from the Index.

Added:

AMAG Pharmaceuticals, Inc., (Nasdaq:AMAG) is a biopharmaceutical company. The Company utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Biodel Inc. (Nasdaq:BIOD) is a pharmaceutical company focused on the development and commercialization of treatments for endocrine disorders such as diabetes and osteoporosis.

MiddleBrook Pharmaceuticals, Inc. (Nasdaq:MBRK) develops and commercializes drug products used in the treatment of infectious disease. The Company's drugs attempt to kill bacteria by exposing it to sequential bursts, or pulses of the medication instead of the standard antibiotic treatment regimens.

Pharmasset, Inc. (Nasdaq:VRUS) is a pharmaceutical company. The Company develops oral therapeutics for the human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV).

Synta Pharmaceuticals Corp. (Nasdaq:SNTA) is a biopharmaceutical company developing small-molecule drugs for inflammatory diseases, cancer, and diabetes. The Company has drug candidates in human clinical trials and additional programs in preclinical studies.

Source:
mondovisione.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Unconventional superconductor may be used to create quantum computers of the future: They have probably succeeded in creating a topological superconductor February 19th, 2018

Photonic chip guides single photons, even when there are bends in the road February 16th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

European & Korean Project To Demo World’s First 5G Platform During Winter Games February 15th, 2018

Investments/IPO's/Splits

Nanowire LED Innovator Aledia Announces €30 ($36M) Million Series-C Financing: Intel Capital Joins Existing Investors to Commercialize Certain Nanowire-LED Technologies for Mobile Displays January 29th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanomedicine

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

Understanding brain functions using upconversion nanoparticles: Researchers can now send light deep into the brain to study neural activities February 14th, 2018

Announcements

Unconventional superconductor may be used to create quantum computers of the future: They have probably succeeded in creating a topological superconductor February 19th, 2018

Photonic chip guides single photons, even when there are bends in the road February 16th, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project